

radioactive compound.

10. (Reiterated) The method of claim 9 wherein the antibody comprises Y2B8 or <sup>125</sup>I-B1.

---

E2 11. (Amended) The method of claim 1 comprising administering the antibody intravenously.

12. (Amended) The method of claim 1 comprising administering the antibody subcutaneously.

13. (Amended) The method of claim 1 comprising administering a dose of substantially less than 375 mg/m<sup>2</sup> of the antibody to the mammal.

---

14. (Reiterated) The method of claim 13 wherein the dose is in the range from about 20 mg/m<sup>2</sup> to about 250 mg/m<sup>2</sup>.

15. (Reiterated) The method of claim 14 wherein the dose is in the range from about 50 mg/m<sup>2</sup> to about 200 mg/m<sup>2</sup>.

---

E3 16. (Amended) The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m<sup>2</sup> dose of the antibody in the subsequent dose exceeds the mg/m<sup>2</sup> dose of the antibody in the initial dose.

---

22. (Reiterated) The method of claim 1 comprising administering the antibody to the mammal before the mammal is exposed to the graft.

28. (Reiterated) A method of treating graft-versus-host or host-versus-graft disease in a mammal comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.

Please cancel claim 31, without prejudice or disclaimer.